US 11,912,645 B2
Lipopeptide compounds for the treatment of pain disorders
Nicolas Cenac, Toulouse (FR); Justine Bertrand-Michel, Toulouse (FR); Teresa Perez-Berezo, Toulouse (FR); Thierry Durand, Montpellier (FR); Jean-Marie Galano, Montpellier (FR); Julien Pujo, Toulouse (FR); Eric Oswald, Toulouse (FR); Patricia Martin, Toulouse (FR); Pauline Le Faouder, Toulouse (FR); and Alexandre Guy, Montpellier (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE, Toulouse (FR); CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE—CNRS—, Paris (FR); ECOLE NATIONALE VETERINAIRE DE TOULOUSE, Toulouse (FR); UNIVERSITE PAUL SABATIER TOULOUSE III, Toulouse (FR); INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT, Paris (FR); UNIVERSITE DE MONTPELLIER, Montpellier (FR); and ECOLE NATIONALE SUPERIEURE DE CHIMIE DE MONTPELLIER, Montpellier (FR)
Appl. No. 16/607,772
Filed by INSERM (Institut National de la Santé et de la Recherche Médicale), Paris (FR); Université Paul Sabatier Toulouse III, Toulouse (FR); Centre National de la Recherche Scientifique (CNRS), Paris (FR); Centre Hospitalier Universitaire de Toulouse, Toulouse (FR); and Ecole Nationale Vétérinaire de Toulouse, Toulouse (FR)
PCT Filed Apr. 27, 2018, PCT No. PCT/EP2018/060873
§ 371(c)(1), (2) Date Oct. 24, 2019,
PCT Pub. No. WO2018/197666, PCT Pub. Date Nov. 1, 2018.
Claims priority of application No. 17305481 (EP), filed on Apr. 28, 2017.
Prior Publication US 2020/0048187 A1, Feb. 13, 2020
Int. Cl. C07C 233/47 (2006.01); A61P 29/00 (2006.01)
CPC C07C 233/47 (2013.01) [A61P 29/00 (2018.01)] 9 Claims
 
1. A compound of Formula (I):
RC(O)-Xaa-Xbb-Y,   Formula (I)
wherein
R is a C5-C19 linear or branched hydrocarbon chain selected from the group consisting of alkyl, alkene, and alkyne,
Xaa is asparagine or an equivalent polar and non-charged amino acid selected from the group consisting of serine, threonine and glutamine,
Xbb is HNCH2CH2CH2CO, and
Y is —OH or NH2,
and wherein Xbb is linked to Xaa through its amine functional group and wherein the RC(O) group of Formula (I) is at the N terminal side and the Y group of Formula (I) is a C terminal side,
or a pharmaceutical acceptable salt thereof.